DKAH 269
Alternative Names: DKAH 269 CLLatest Information Update: 11 Feb 2000
At a glance
- Originator Boehringer Ingelheim
- Developer Boehringer Ingelheim; Boehringer Ingelheim Pharma KG
- Class Anti-ischaemics; Antiarrhythmics
- Mechanism of Action Potassium channel antagonists; Sodium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Ischaemic heart disorders; Tachycardia
Most Recent Events
- 11 Feb 2000 No-Development-Reported for Ischaemic heart disorders in Germany (Unknown route)
- 11 Feb 2000 No-Development-Reported for Tachycardia in Germany (Unknown route)
- 27 Feb 1997 Preclinical development for Ischaemic heart disorders in Germany (Unknown route)